secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0001641172-25-014320
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Hepion appoints director Kaouthar Lbiati as interim CEO effective June 16
-------------------------------------------------------------------------

- Dr. Kaouthar Lbiati, a board member since June 2022, appointed interim CEO effective June 16, 2025.
- Initial term of 3 months; annual base salary $350,000 with $50,000 deferred until equity financing ≥$3M or departure.
- Performance bonus eligible at 35% of base salary upon milestones; pro-rated bonus if terminated without cause before term end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000164117225014320/0001641172-25-014320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000164117225014320/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-014320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer